Paid Clinical Trials Glendale
Discover 3,240 paid clinical trials in Glendale, California. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Standard Care & BR-ACNon-healing Venous Leg Ulcers Treated With Standard Care With or Without BR-AC
Sponsor:
BioStem Technologies
Location:
Code:
NCT06811909
Conditions
Non-infected Venous Leg Ulcer
Venous Leg Ulcer
Venous Insufficiency
Venous Stasis
Venous Reflux
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
BR-AC
Standard Care
AZD4144A Phase 1b Study to Assess the Safety, Tolerability, and Pharmacodynamics of AZD4144 in Participants With Established Atherosclerotic Cardiovascular and Chronic Kidney Disease.
Sponsor:
AstraZeneca
Location:
Code:
NCT06675175
Conditions
Chronic Kidney Disease
Atherosclerotic Cardiovascular Disease
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
AZD4144
Placebo
GS-0272Study of GS-0272 in Participants With Rheumatoid Arthritis
Sponsor:
Gilead Sciences
Location:
Code:
NCT06031415
Conditions
Rheumatoid Arthritis
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
GS-0272
Placebo
AV-101 & ProbenecidAV-101 Alone and in Combination With Probenecid in Healthy Subjects
Sponsor:
VistaGen Therapeutics, Inc.
Location:
Code:
NCT05280054
Conditions
Drug Drug Interaction
Eligibility Criteria
Sex: All
Age: 18 - 55
Healthy Volunteers: Accepted
Interventions
AV-101
Probenecid
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Rilvegostomig & PembrolizumabA Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Sponsor:
AstraZeneca
Location:
Code:
NCT06692738
Conditions
Non-small Cell Lung Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Rilvegostomig
Pembrolizumab
Carboplatin
Paclitaxel
Nab-paclitaxel
AZD8965A Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of AZD8965 in Healthy Participants (Including Japanese and Chinese Participants) and an Open-label Cohort to Assess the Effect of Food on the Pharmacokinetics of AZD8965 in Healthy Participants
Sponsor:
AstraZeneca
Location:
Code:
NCT06502379
Conditions
Healthy Participants
Eligibility Criteria
Sex: All
Age: 18 - 55
Healthy Volunteers: Accepted
Interventions
AZD8965
Placebo
Bomedemstat vs. BATA Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)
Sponsor:
Merck Sharp & Dohme LLC
Location:
Code:
NCT06079879
Conditions
Essential Thrombocythemia
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Bomedemstat
Anagrelide
Busulfan
Interferon alfa/pegylated interferon alfa
Ruxolitinib
B1344A Trial to Evaluate the Safety Tolerability and Pharmacokinetics of B1344 by Subcutaneous Injection in Healthy Subjects
Sponsor:
Tasly Biopharmaceuticals Co., Ltd.
Location:
Code:
NCT05655221
Conditions
Nonalcoholic Steatohepatitis
Eligibility Criteria
Sex: All
Age: 18 - 55
Healthy Volunteers: Accepted
Interventions
B1344
Placebo
LUT014LUT014 for the Reduction of Dose-Limiting Acneiform Lesions Associated With EGFRI Treatment of mCRC
Sponsor:
Lutris Pharma Ltd.
Location:
Code:
NCT04759664
Conditions
EGFRI Induced Acneiform Lesions
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
LUT014 Gel (Dose 1)
LUT014 Gel (Dose 2)
Placebo